OncoTargets and therapyPub Date : 2024-08-22eCollection Date: 2024-01-01DOI: 10.2147/OTT.S470892
Monica Valente, Maura Colucci, Virginia Vegni, Valentina Croce, Cristiana Bellan, Giulia Rossi, Giulia Gibilisco, Francesco Frongia, Raffaella Guazzo, Claudia Ghiribelli, Elena Bargagli, Vinno Savelli, Matteo Ravara, Tommaso Sani, Elena Simonetti, Michele Maio, Luana Calabrò, Anna Maria Di Giacomo
{"title":"A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis.","authors":"Monica Valente, Maura Colucci, Virginia Vegni, Valentina Croce, Cristiana Bellan, Giulia Rossi, Giulia Gibilisco, Francesco Frongia, Raffaella Guazzo, Claudia Ghiribelli, Elena Bargagli, Vinno Savelli, Matteo Ravara, Tommaso Sani, Elena Simonetti, Michele Maio, Luana Calabrò, Anna Maria Di Giacomo","doi":"10.2147/OTT.S470892","DOIUrl":"10.2147/OTT.S470892","url":null,"abstract":"<p><strong>Purpose: </strong>Treatment with immune-checkpoint inhibitors (ICIs) can be associated with a wide spectrum of immune-related adverse events (irAEs). Among irAEs, immune-mediated pneumonitis (im-PN) is a rare but potentially life-threatening side effect. TPrompt multidisciplinary diagnosis and effective management of im-PN may be essential to avoid severe complications and allowing resumation of therapy.</p><p><strong>Patients and methods: </strong>We collected a case series of skin (melanoma, cutaneous squamous cell carcinoma-CSCC), lung, and mesothelioma cancer patients (pts), treated with ICI at the Center for Immuno-Oncology University Hospital of Siena, Italy, and diagnosed with im-PN. Clinical and radiologic data were thoroughly collected, as well as bronchoalveolar lavage (BAL) samples; im-PN was graded using CTCAE v. 5.0. Radiological patterns were reported according to the <i>F</i>leischner Society classification.</p><p><strong>Results: </strong>From January 2014 to February 2023, 1004 patients with melanoma (522), CSCC (42), lung (342) or mesothelioma (98) were treated with ICI (619 monotherapy; 385 combination). Among treated patients, 24 (2%) developed an im-PN and 58% were symptomatic. Im-PN were classified as grades G1 (10) and G2 (14). Prompt steroid treatment led to complete resolution of im-PN in 21 patients, with a median time to resolution of 14 weeks (range: 0.4-51). Twelve patients resumed ICI therapy once fully-recovered and 2 experienced a recurrence that completely resolved with steroids after resumption of treatment. Three radiologic patterns were identified: organizational pneumonia-like (67%), pulmonary eosinophilia (29%), and hypersensitivity pneumonitis (4%). Furthermore, BAL analysis performed in 8 (33%) patients showed an inflammatory lymphocytic infiltrate, predominantly consisting of foam cell-like macrophage infiltrates in 6 cases. Notably, transmission electron microscopy evaluation performed in 2 patients revealed a scenario suggestive of a drug-mediated toxicity.</p><p><strong>Conclusion: </strong>Im-PN is a rare but challenging side effect of ICI therapy, with variable time of onset and with heterogeneous clinical and radiological presentations. A multidisciplinary assessment is mandatory to optimize the clinical management of im-PN.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"673-681"},"PeriodicalIF":2.7,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncoTargets and therapyPub Date : 2024-08-20eCollection Date: 2024-01-01DOI: 10.2147/OTT.S491281
{"title":"TRIM31 Promotes Glioma Proliferation and Invasion Through Activating NF-κB Pathway [Retraction].","authors":"","doi":"10.2147/OTT.S491281","DOIUrl":"https://doi.org/10.2147/OTT.S491281","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/OTT.S183625.].</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"671-672"},"PeriodicalIF":2.7,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncoTargets and therapyPub Date : 2024-08-14eCollection Date: 2024-01-01DOI: 10.2147/OTT.S491280
{"title":"G-Protein-Signaling Modulator 2 Expression and Role in a CD133<sup>+</sup> Pancreatic Cancer Stem Cell Subset [Retraction].","authors":"","doi":"10.2147/OTT.S491280","DOIUrl":"https://doi.org/10.2147/OTT.S491280","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/OTT.S187670.].</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"667-668"},"PeriodicalIF":2.7,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncoTargets and therapyPub Date : 2024-08-14eCollection Date: 2024-01-01DOI: 10.2147/OTT.S491282
{"title":"circHIPK<sub>3</sub> Promotes Cell Proliferation and Migration of Gastric Cancer by Sponging miR-107 and Regulating BDNF Expression [Retraction].","authors":"","doi":"10.2147/OTT.S491282","DOIUrl":"https://doi.org/10.2147/OTT.S491282","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/OTT.S226300.].</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"669-670"},"PeriodicalIF":2.7,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11330851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Combination of Sintilimab and Anlotinib for Metastatic Osteosarcoma: A Case Report.","authors":"Gaoyan Tang, Qianqian Zhang, Fengxia Wang, Hua Zhang, Yuanling Qi","doi":"10.2147/OTT.S464678","DOIUrl":"10.2147/OTT.S464678","url":null,"abstract":"<p><strong>Background: </strong>As one of the most common types of primary bone sarcomas in adolescents and young adults, osteosarcoma has a high probability of local invasion and distant metastasis with a poor prognosis.</p><p><strong>Case presentation: </strong>Here, we report the case of a 34-year-old patient with advanced metastatic osteosarcoma. Considering the high expression of PD-L1 and the inability of the patient to tolerate chemotherapy, anti-PD-1 antibody (sintilimab 200 mg, q3w) and anti-angiogenesis drug (anlotinib 8 mg D1-14, q3w) were administered. The metastatic lesions were treated with local radiotherapy. The patient obtained an 11.7-month-sustained remission period, and he also enjoyed a better quality of life.</p><p><strong>Conclusion: </strong>This case demonstrates that sintilimab plus anlotinib may be a feasible treatment regimen for osteosarcoma patients.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"661-665"},"PeriodicalIF":2.7,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ke Lei, Bing Ma, Ping Shi, Che Jin, Tan Ling, Longjiang Li, Xiangyi He, Lunchang Wang
{"title":"Icariin Mitigates the Growth and Invasion Ability of Human Oral Squamous Cell Carcinoma via Inhibiting Toll-Like Receptor 4 and Phosphorylation of NF-κB P65 [Retraction]","authors":"Ke Lei, Bing Ma, Ping Shi, Che Jin, Tan Ling, Longjiang Li, Xiangyi He, Lunchang Wang","doi":"10.2147/ott.s490273","DOIUrl":"https://doi.org/10.2147/ott.s490273","url":null,"abstract":"Retraction for the article Icariin Mitigates the Growth and Invasion Ability of Human Oral Squamous Cell Carcinoma via Inhibiting Toll-Like Receptor 4 and Phosphorylation of NF-κB P65","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"1 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141930506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"MiR-181c-5p Mitigates Tumorigenesis in Cervical Squamous Cell Carcinoma via Targeting Glycogen Synthase Kinase 3β Interaction Protein (GSKIP) [Retraction]","authors":"Niuniu Li, Chun Cheng, Tieyan Wang","doi":"10.2147/ott.s490276","DOIUrl":"https://doi.org/10.2147/ott.s490276","url":null,"abstract":"Retraction for the article MiR-181c-5p Mitigates Tumorigenesis in Cervical Squamous Cell Carcinoma via Targeting Glycogen Synthase Kinase 3β Interaction Protein (GSKIP)","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"12 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141930505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Down-Regulation of ZEB1 by miR-199a-3p Overexpression Restrains Tumor Stem-Like Properties and Mitochondrial Function of Non-Small Cell Lung Cancer [Retraction]","authors":"Juan Bai, Wen-Yu Jiao","doi":"10.2147/ott.s490275","DOIUrl":"https://doi.org/10.2147/ott.s490275","url":null,"abstract":"Retraction for the article Down-Regulation of ZEB1 by miR-199a-3p Overexpression Restrains Tumor Stem-Like Properties and Mitochondrial Function of Non-Small Cell Lung Cancer","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"91 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141930507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer.","authors":"Xiao Wei, Yun Zhao, Wenyue Yan, Qigang Dai, Hui Wu, Yang Miao, Lei Huang, Qing Liu, Xuyao Zhang, Hongxia Wang, Yanan Liu, Linlin Zhang","doi":"10.2147/OTT.S468932","DOIUrl":"10.2147/OTT.S468932","url":null,"abstract":"<p><strong>Background: </strong>Anlotinib and apatinib, both vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), are clinically established in the treatment of advanced non-small cell lung cancer (NSCLC) in China, with anlotinib emerging as a standard treatment strategy. This study was conducted to evaluate the efficacy and safety of apatinib and anlotinib, and to compare their differences in treating patients with advanced NSCLC.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed the data of patients with advanced NSCLC treated with apatinib or anlotinib at a hospital in Eastern China from January 2017 to December 2021. The primary endpoint was progression-free survival (PFS), while secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety profile.</p><p><strong>Results: </strong>A total of 145 patients were included in this study. Median PFS (mPFS) was 3.53 months for the apatinib group and 5.3 months for the anlotinib group (HR = 0.59, 95% CI: 0.41-0.84; P = 0.004), and median OS (mOS) was 7.6 months versus 15.6 months (HR = 0.68, 95% CI: 0.46-1.00; P = 0.048), which all showed significant differences after adjusting for confounders (P < 0.05). Subgroup analysis revealed that the presence or absence of bone metastases significantly influenced PFS in both treatment groups. The ORR was 3.03% in the anlotinib group versus 10.13% in the apatinib group (P = 0.12), the DCR was 72.73% versus 51.90% (P = 0.21). No unanticipated adverse events (AEs) were observed. The incidence of grade 3-4 AEs was significantly higher in the apatinib group (31.65% vs 13.64%, P < 0.05).</p><p><strong>Conclusion: </strong>Anlotinib demonstrated greater efficacy and safety compared to apatinib in the treatment of advanced NSCLC, particularly in patients with bone metastases and EGFR(-).</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"629-642"},"PeriodicalIF":2.7,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11316477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncoTargets and therapyPub Date : 2024-08-06eCollection Date: 2024-01-01DOI: 10.2147/OTT.S474038
Xu Huang, Feihan Gu, Mingyu Zhao, Wenkai Huang, Wenjia Han, Ran Chen, Yuanyin Wang
{"title":"Function and Therapeutic Potential of Non-Coding RNA in Ameloblastoma.","authors":"Xu Huang, Feihan Gu, Mingyu Zhao, Wenkai Huang, Wenjia Han, Ran Chen, Yuanyin Wang","doi":"10.2147/OTT.S474038","DOIUrl":"10.2147/OTT.S474038","url":null,"abstract":"<p><p>Ameloblastoma (AB) is a common odontogenic tumor that develops in the mouth. Despite its benign nature, AB exhibits significant invasiveness leading to tumor metastasis and high postoperative recurrence rates. Studies have shown a relationship between the occurrence and development of various tumors and non-coding RNA (ncRNA). NcRNA, transcribed from the genomes of mammals and other complex organisms, are often products of alternative splicing and processing into smaller products. MicroRNA (miRNA), circular RNA (circRNA), and long non-coding RNA (lncRNA) are the main types of ncRNA. NcRNA play increasingly significant roles in the pathogenesis of human cancers, regulating their occurrence and progression as oncogenes or tumor suppressors. They are involved in tumor development and progression through alternative splicing of pre-mRNA, transcriptional regulation, mRNA stability, protein translation, and chromatin remodeling and modification. The importance of ncRNA in AB has received significant attention in recent years. However, the biological functions and mechanisms of ncRNA in AB remain largely unknown. In this review, we not only explore the functions and roles of ncRNA in AB, but also describe and envision their potential functional roles as biomarkers in AB diagnosis. In particular, we highlight the potential of miR-29a as a molecular marker for diagnosis and therapy. As promising novel therapeutic targets, the biological functions of ncRNA need further study, which is indispensable.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"643-653"},"PeriodicalIF":2.7,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11316470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}